Section: New Results

Analysis of results from Clinical trials and cohorts

In the HIV field

We have performed the statistical analyses of the immunogenicity endpoints, including high dimensional assays such as gene expression (RNA Seq), of two HIV vaccine clinical trials: 1) ANRS VRI01, a randomized phase I/II trial evaluating for different prime boost vaccine strategies in healthy volunteers; 2) ANRS 159 LIGHT, a randomized phase II trial comparing a prime-boost therapeutic HIV vaccine strategy to placebo in HIV-infected patients undergoing antiretroviral treatment interruption. The results of each of these two trials have been presented as an oral presentation at the HIV R4P conference in Madrid in October 2018 (Richert L et al. and Lacabaratz C et al). Integrative statistical analyses using sPLS methods (as developed by the team) are currently ongoing to relate markers from different high-dimensional immunogenicity assays or virological assays to each other.

In the Ebola field

We have performed a review of all existing clinical trials available to evaluate Ebola vaccines in macaques and humans.

Gross L, Lhomme E, Pasin C, Richert L, Thiébaut R. Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. International Journal of Infectious Diseases. 2018. pii: S1201-9712(18)34457-6.

In cluster randomized trials

Accounting for missing outcome is highly important to recover unbiased results of treatment effects. Weighting approached are less common compared to multilevel multiple imputation to analyse clustered data with missing outcome. >In collaboration with Duke University, we compared the two approaches and evaluated their performances to conclude that weighted appraoch should be considered a viable strategy to account for missing outcomes in cluster randomized trials

In cluster randomized trials, it is often desirable to improve the understanding of intervention effects in the presence of dissemination/spillover. In collaboration with Rhode Island university and Yale University, we aims at proposing innovative approach to analyze the TasP ANRS 12249 trial.We proposed innovative methods to individual, disseminated and overal effect of a clustered intervention based on counterfactuals averages in the presence of dissemination.